StreetSmart Live! Presents Metallic Group of Companies on 01/26/2021. Learn More

Streetwise Biotech / Pharmaceuticals Articles

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports  (1/25/21)
Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis. More >

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports  (1/22/21)
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. More >

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
Source: Streetwise Reports  (1/20/21)
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. More >

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports  (1/20/21)
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. More >

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin
Source: Streetwise Reports  (1/19/21)
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. More >

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial
Source: Streetwise Reports  (1/19/21)
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. More >

Neurosciences Firm Outlines Strategic Priorities for 2021
Source: Streetwise Reports  (1/15/21)
ProMIS Neurosciences discusses its four priority areas in 2021. More >

As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry
Source: Streetwise Reports  (1/13/21)
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. More >

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients
Source: Streetwise Reports  (1/11/21)
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. More >

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (1/11/21)
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of Can it go the distance through proof of concept? More >

Pharma Developer Outlines 2021 Clinical Program Initiatives
Source: Streetwise Reports  (1/8/21)
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. More >

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition
Source: Streetwise Reports  (1/8/21)
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. More >

Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results
Source: Streetwise Reports  (1/6/21)
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report. More >

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
Source: Streetwise Reports  (1/4/21)
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil. More >

Biopharma Appoints Adviser for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (1/4/21)
Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team. More >

Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial
Source: Streetwise Reports  (1/4/21)
Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus. More >

California Biotech Advances Two COVID-19 Products
Source: Streetwise Reports  (12/30/20)
Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report. More >

Biotech On Track for Trio of Drugs in Clinical Trials in 2021
Source: Streetwise Reports  (12/30/20)
The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report. More >

Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review
Source: Streetwise Reports  (12/29/20)
Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication. More >

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer
Source: Streetwise Reports  (12/28/20)
Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada. More >

Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy
Source: Streetwise Reports  (12/23/20)
The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report. More >

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher
Source: Streetwise Reports  (12/23/20)
Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder. More >

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program
Source: Streetwise Reports  (12/22/20)
Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program. More >

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
Source: Streetwise Reports  (12/21/20)
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial. More >

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties
Source: Streetwise Reports  (12/21/20)
Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties. More >

Showing Results: 1 to 25 of 1309 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"GENM's hole 548 cut 8m of 3.9 g/t Pd, 1.4 g/t Pt and 0.43 g/t Au."
– Brien Lundin, Gold Newsletter (Jefferson Financial)